| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2008 | CA2654583A1 Mtki quinazoline derivatives |
| 01/17/2008 | CA2635903A1 Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity |
| 01/16/2008 | EP1878804A1 Perkinson disease-related gene grk5 and use thereof |
| 01/16/2008 | EP1878754A1 Preparation and application of heparin silver |
| 01/16/2008 | EP1878753A1 Acerola fruit-derived pectin and use thereof |
| 01/16/2008 | EP1878746A2 Human monoclonal antibodies to epidermal growth factor receptor |
| 01/16/2008 | EP1878738A1 Allergy-suppressive composition, allergy-suppressive food and allergy-suppressive agent |
| 01/16/2008 | EP1878734A1 Novel lactam compound |
| 01/16/2008 | EP1878733A1 Pyrimidine derivatives as ALK-5 inhibitors |
| 01/16/2008 | EP1878732A1 HIGHLY SELECTIVE Rho-KINASE INHIBITOR |
| 01/16/2008 | EP1878730A1 Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| 01/16/2008 | EP1878728A2 Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders |
| 01/16/2008 | EP1878727A1 2-aminoquinazoline derivatives |
| 01/16/2008 | EP1878726A1 Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
| 01/16/2008 | EP1878725A2 Pyrimidine derivatives and their use as CB2 modulators |
| 01/16/2008 | EP1878723A1 N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide derivatives antagonists of the CB1 cannabinoids receptors |
| 01/16/2008 | EP1878722A1 Quinolinone derivatives and their pharmaceutical compositions |
| 01/16/2008 | EP1878721A1 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| 01/16/2008 | EP1878720A1 Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors |
| 01/16/2008 | EP1878719A1 Crystal polymorph of hydroxynorephedrin derivative hydrochloride |
| 01/16/2008 | EP1878717A1 Benzyl amines, a process for their production and their use as anti-inflammatory agents |
| 01/16/2008 | EP1878664A1 Process for producing metered dose inhaler formulations |
| 01/16/2008 | EP1878446A2 Formulation comprising buprenorphine |
| 01/16/2008 | EP1878444A1 Composition containing antidementia agent |
| 01/16/2008 | EP1878443A1 Therapeutic agent for neuropathic pain |
| 01/16/2008 | EP1878442A1 Method for treating body fluid |
| 01/16/2008 | EP1878440A1 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| 01/16/2008 | EP1878435A1 Composition for inducing sleep containing vegetable essential oil component as the active component, transdermal absorption type sleep inducing agent containing the composition and method of producing the same |
| 01/16/2008 | EP1878432A1 Single dose fast dissolving azithromycin |
| 01/16/2008 | EP1878431A1 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues |
| 01/16/2008 | EP1878430A1 Peritoneal dialysis fluid |
| 01/16/2008 | EP1878429A1 Trenadermal absorption preparation |
| 01/16/2008 | EP1878428A1 1-(substituted phenyl)-5- methyl- 2 - (1h) pyridone in the manufacture of medicaments for treating fibrosis in organs or tissues |
| 01/16/2008 | EP1878427A1 Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure |
| 01/16/2008 | EP1878426A1 Granular preparation containing biguanide compound |
| 01/16/2008 | EP1878425A1 Transdermal absorption accelerator |
| 01/16/2008 | EP1878421A1 External preparation for skin |
| 01/16/2008 | EP1878044A2 Xerogel films for the controlled release of pharmaceutically active molecules |
| 01/16/2008 | EP1877556A2 USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN |
| 01/16/2008 | EP1877555A2 Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure. |
| 01/16/2008 | EP1877553A2 Polymer conjugate enhanced bioassays |
| 01/16/2008 | EP1877422A1 Green tea polyphenol alpha secretase enhancers and methods of use |
| 01/16/2008 | EP1877420A1 Combination therapy in the treatment of cancer |
| 01/16/2008 | EP1877419A2 Polymorphic and amorphous salt forms of squalamine dilactate |
| 01/16/2008 | EP1877411A2 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| 01/16/2008 | EP1877410A1 Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity |
| 01/16/2008 | EP1877409A2 Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof |
| 01/16/2008 | EP1877408A1 Imidazo [1, 2-a]pyridine derivatives useful as peptide deformylase (pdf) inhibitors |
| 01/16/2008 | EP1877407A1 Imidazo(1,2-a)pyridine derivatives useful as peptide deformylase (pdf) inhibitors |
| 01/16/2008 | EP1877406A1 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents |
| 01/16/2008 | EP1877405A1 Benzisoxazole piperidine compounds and methods of use thereof |
| 01/16/2008 | EP1877404A2 Novel cyclic amines |
| 01/16/2008 | EP1877403A1 Mono-lysine salts of azole compounds |
| 01/16/2008 | EP1877400A1 Vanilloid receptor ligands and their use in treatments |
| 01/16/2008 | EP1877399A1 Triazole derivatives as vasopressin antagonists |
| 01/16/2008 | EP1877398A1 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors |
| 01/16/2008 | EP1877397A1 Quinazoline derivatives as inhibitors of egf and/or erbb2 receptor tyrosine kinase |
| 01/16/2008 | EP1877391A1 Pro-drugs of n-thiazol-2yl-benzamide derivatives |
| 01/16/2008 | EP1877390A1 Benzisoxazole piperazine compounds and methods of use thereof |
| 01/16/2008 | EP1877388A2 Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| 01/16/2008 | EP1877385A1 Pyrimidines and pyrazines useful as modulators of ion channels |
| 01/16/2008 | EP1877384A2 Method for preparation of optionally 2-substituted 1,6-dihydro-6-oxo-4-pyrimidinecarboxylic acids |
| 01/16/2008 | EP1877383A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity |
| 01/16/2008 | EP1877381A1 Pyridines useful as modulators of ion channels |
| 01/16/2008 | EP1877379A1 Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
| 01/16/2008 | EP1877376A1 Novel compounds for treating inflammatory diseases |
| 01/16/2008 | EP1877373A2 Biphenylazetidinone cholesterol absorption inhibitors |
| 01/16/2008 | EP1877372A1 Water-dispersible carotenoids, including analogs and derivatives |
| 01/16/2008 | EP1877369A2 Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
| 01/16/2008 | EP1877367A1 Acetylene derivatives |
| 01/16/2008 | EP1877366A1 Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity |
| 01/16/2008 | EP1877365A1 Acetylene derivatives |
| 01/16/2008 | EP1877141A2 Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria |
| 01/16/2008 | EP1877092A2 Delivery of tigecycline in the presence of warfarin |
| 01/16/2008 | EP1877091A1 Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
| 01/16/2008 | EP1877070A2 Dosage of oligonucleotides |
| 01/16/2008 | EP1877069A2 Novel use of spiegelmers |
| 01/16/2008 | EP1877068A2 Nicotinamide riboside kinase compositions and methods for using the same |
| 01/16/2008 | EP1877067A1 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
| 01/16/2008 | EP1877066A1 Use of azithromycin for the production of a medicament for treatment of ocular infections |
| 01/16/2008 | EP1877065A2 Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
| 01/16/2008 | EP1877064A2 Delivery of tigecycline in the presence of heparin |
| 01/16/2008 | EP1877063A2 19,26,27-trinor-1alpha ,25-dihydroxyvitamin d3 compounds |
| 01/16/2008 | EP1877062A1 Extended estrogen dosing contraceptive regimen |
| 01/16/2008 | EP1877061A2 Method and composition for inhibiting cell proliferation and angiogenesis |
| 01/16/2008 | EP1877060A2 Therapeutic bifunctional compounds |
| 01/16/2008 | EP1877059A2 Micronized tanaproget and compostions containing same |
| 01/16/2008 | EP1877058A2 Use of phycotoxins in veterinary applications |
| 01/16/2008 | EP1877057A1 Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
| 01/16/2008 | EP1877055A2 4-aminoquinoline compounds for treating virus-related conditions |
| 01/16/2008 | EP1877054A2 Nicotinamide riboside and analogues thereof |
| 01/16/2008 | EP1877053A2 Combination formulation |
| 01/16/2008 | EP1877052A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 01/16/2008 | EP1877051A1 MATRIX METALLOPROTEINASE INHIBITORS OF TGFß -INDUCED SUBCAPSULAR CATARACT FORMATION |
| 01/16/2008 | EP1877050A1 Substituted beta-lactams and their use in medicine |
| 01/16/2008 | EP1877049A2 Inclusion compounds of dioclein, floranol or analogs with cyclodextrin and their use for treating cardiovascular diseases |
| 01/16/2008 | EP1877048A1 Combination cancer therapy with bis(thiohydrazide) amide compounds |
| 01/16/2008 | EP1877047A2 Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition |
| 01/16/2008 | EP1877045A2 Methods of treating atherosclerosis |
| 01/16/2008 | EP1877044A2 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |